In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

STICS - Short-term peri-operative statin treatment does not reduce complications after cardiac surgery

High-dose statin treatment around the time of cardiac surgery does not reduce the rate of in-hospital complications after cardiac surgery, according to the results of a new study presented today as a Hot Line at ESC Congress 2014.

Atrial Fibrillation


BARCELONA, Spain – Tuesday 2 September 2014: High-dose statin treatment around the time of cardiac surgery does not reduce the rate of in-hospital complications after cardiac surgery, according to the results of a new study presented today as a Hot Line at ESC Congress 2014.
The lack of benefit in the Statin Therapy In Cardiac Surgery (STICS) Trial is a bit of a surprise, said lead investigator Barbara Casadei, MD, DPhil, from the John Radcliffe Hospital, University of Oxford, UK.

“Previous small randomised trials had suggested that peri-operative statin therapy might halve the likelihood of developing atrial fibrillation after cardiac surgery, as well as preventing damage to the heart muscle and kidney failure,” said Professor Casadei. “We expected there to be beneficial results in STICS, although it seemed likely they would be more modest than the initial trials. STICS was twice as big as all the previous trials combined and involved particularly careful and systematic assessment of post-operative complications. Despite this we found no evidence of benefit from peri-operative statin therapy.”

The STICS results have important implications for peri-operative practice and guidelines in cardiac surgery, added co-lead investigator Zhe Zheng, MD, PhD, Deputy Director of Cardiovascular Surgery at the Fuwai Hospital, Chinese Academy of Medical Sciences in Beijing, China.

“They show that initiating high-dose statin therapy in the peri-operative period in order to avoid common post-operative complications is not warranted. They also show that, in subjects randomised to placebo, stopping statin therapy in the peri-operative period does not have a negative impact on such complications. Overall, the results of STICS do not endorse routine use of short-term statin therapy to prevent in-hospital complications in patients undergoing major surgery,” he said.

However, Professor Casadei added that “starting statins for the purpose of lowering cholesterol in the medium to long term is beneficial because it reduces heart attacks and stroke. So doctors should continue to prescribe statins for this purpose even if not to prevent in-hospital complications after cardiac surgery”.
The STICS trial was a collaborative project between the National Centre for Cardiovascular Diseases at the Fuwai Hospital in Beijing, and the University of Oxford. It included 1922 patients (mean age was 59.4 years) who were undergoing elective cardiac surgery. Patients were randomised to receive either rosuvastatin (20 mg daily) or placebo, starting up to eight days before surgery and continuing until the fifth postoperative day.
Compliance with the study treatment was high (98% at the end of the scheduled treatment period) and allocation to the high-dose rosuvastatin regimen rapidly produced a substantial (25%) reduction in cholesterol compared with placebo (p <0.0001 by 48 hours after surgery).
New-onset atrial fibrillation - an abnormal heart rhythm linked to stroke - was the co-primary outcome of the study, and for this endpoint there were no differences between the rosuvastatin and placebo groups (21% vs 20%, respectively; p= 0.72). Similarly, for the other co-primary outcome, serum levels of troponin I - an indication of peri-operative injury to the heart muscle - there were also no differences between the groups (p = 0.72).  
Pre-specified sub-group analyses did not identify any groups of patients who benefited from peri-operative statin use, and the treatment did not have any beneficial impact on secondary outcomes such as length of hospital stay, major in-hospital cardiac or cerebrovascular events, left ventricular function (by echocardiography) and plasma creatinine.
Despite advances in surgical and peri-operative care, post-operative complications remain frequent and lead to a significant increase in mortality, disability, and costs, Professor Casadei concluded.

“Previous studies suggested that short-term peri-operative statin treatment may be beneficial in this regard; however, STICS offers definitive evidence against this notion. Overall, STICS reinforces the need to carry out large trials to confirm the results of smaller studies in selected groups of patients.”

ENDS

Notes to editor

About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
About ESC Congress 2014
The ESC Congress is currently the world's largest international congress in cardiovascular medicine.  The spotlight of this year's event is “innovation and the heart”.  ESC Congress 2014 takes place from 30 August to 3 September at the Fira Gran Via in Barcelona, Spain. For more information on ESC Congress 2014 contact the ESC Press Office.
To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.
ESC TV: Watch Prof Casadei's interview
This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2014. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.
SOURCES OF FUNDING: STICS was an investigator-lead trial that was funded by the British Heart Foundation, the European Network for Translational Research in Atrial Fibrillation (FP7 EUTRAF), the Oxford Biomedical Research Centre, the Medical Research Council, UK and an unrestricted ($100K) grant from Astra Zeneca.
DISCLOSURES: Oxford University received the unrestricted grant from Astra Zeneca.